Weekly Analysts’ Ratings Updates for Omnicell (OMCL)

A number of firms have modified their ratings and price targets on shares of Omnicell (NASDAQ: OMCL) recently:

• 5/10/2026 – Omnicell was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/7/2026 – Omnicell was upgraded by Weiss Ratings from “sell (d)” to “hold (c-)”.
• 5/2/2026 – Omnicell was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/1/2026 – Omnicell was upgraded by Zacks Research from “hold” to “strong-buy”.
• 4/29/2026 – Omnicell had its “buy” rating reaffirmed by Craig Hallum. They now have a $55.00 price target on the stock.
• 4/28/2026 – Omnicell had its price target raised by KeyCorp from $60.00 to $70.00. They now have an “overweight” rating on the stock.
• 4/23/2026 – Omnicell had its price target raised by Wells Fargo & Company from $52.00 to $55.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling at Omnicell

In related news, EVP Corey J. Manley sold 5,025 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $217,180.50. Following the sale, the executive vice president owned 112,783 shares of the company’s stock, valued at $4,874,481.26. The trade was a 4.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $133,549.80. Following the sale, the executive vice president directly owned 154,785 shares in the company, valued at $6,689,807.70. This trade represents a 1.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 15,520 shares of company stock worth $607,610. 2.92% of the stock is currently owned by insiders.

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.